Holzkirchen, Germany, February 24, 2014 – Sandoz officially opened its representative office in Accra, Ghana on January 23, 2014.
The ceremony was attended by healthcare professionals including pharmacists, doctors, the Ghana health service, the Ministry of health, as well as Brigitte Cuendet, the Counsellor and Head of Economic Affairs at the Swiss Embassy in Ghana, and Edith Gavor, manager of the Ghana National Drug Programme (GNDP).
Ms …
February 17, 2014 – Sandoz has been recognized by various organizations for its achievements in creating an inclusive workplace.
Holzkirchen, Germany, February 12, 2014 – Sandoz announced it has received marketing authorization in Belgium for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.
The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received in Germany, Sweden, Hungary, Romania, Bulgaria, and Norway.
The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.
Belgium has …
Holzkirchen, Germany, February 10, 2014 – Sandoz announced today it has received Norwegian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.
The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Sweden, Hungary, Romania and Bulgaria.
The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.
Norway has approved the 50/250µg and 50/ …
Princeton, New Jersey, February 5, 2014 – Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol®.
Doxercalciferol injection vials are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.1
“Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US,” said Peter Goldschmidt, President of Sandoz Inc.
Sandoz is marketing …
February 4, 2014 – Today Sandoz recognizes World Cancer Day. Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008, according to the World Health Organization. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 million deaths in 2030.
The high cost of treating cancer can be a significant barrier to patients. Well over half of all cancer deaths (70%) in 2008 occurred in low- and middle-income countries, according to the World Health Organization. Sandoz oncology injectables …
Holzkirchen, Germany, February 4, 2014 – Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.
The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.
In January, 2014 Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden, Hungary and …
Basel, January 29, 2014 – Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects.
Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.
The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.
Earlier this month, Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden and Hungary. …
Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.
The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.
Earlier this month, Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden and Hungary. …
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia